Value Investor
Start free

Precision Biosciences

DTIL on Nasdaq. Biological products, (no diagnostic substances). Market value $174m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

Nothing stands out yet.

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-30.3%low

For every $100 of what the whole company costs, it produced $-30.35 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 40 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$6.20 a share, 76% above its 1-year low

Over the past year the price has ranged from $3.53 to $9.62.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.0
-0.0
-0.1
-0.1
-0.1
-0.1
2021202220232024202512 monthsto Jun '26
Revenue
$116m$25m$49m$69m$34m
Operating margin
-34.1%-248.3%-89.8%-38.1%-152.2%
Debt to equity
0.030.37n/an/an/a
Shares outstanding
0.11bn0.12bn0.01bn0.01bn0.03bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting checksSkipped: company is not yet profitable
  • DebtUnknown
  • Revenue growth, five yearsSlow, 7.1% a year
  • Buying back its own sharesYes, 75% fewer since 2021

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $0 last quarter, down 100% on a year ago.
  • A loss of $33 million, compared with a loss of $24 million a year ago.
  • It loses 81 cents on each $1 of sales, compared with 7146 cents a year earlier.
  • Over the past 12 months it spent $52 million more cash than it brought in, compared with $64 million a year earlier.
  • 134% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in 2 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
September 2024$576,000
December 2024$638,000
March 2025$29,000
June 2025$18,000
September 2025$13,000
December 2025$34m
March 2026$11m
June 2026$0
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$16m
December 2024-$18m
March 2025-$21m
June 2025-$24m
September 2025-$22m
December 2025$20m
March 2026-$18m
June 2026-$33m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
12 March 2026
Next quarterly (estimated, 10-Q)
5 November 2026

Who owns it

None of the long-term investors we follow own it. 95 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

7 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 3 insiders bought $63,215 of shares on the open market. 4 sold $466,167, $466,167 of it under preset trading plans.

Cluster buy3 insiders bought within 30 days (25 September 2026 to 28 September 2026).
  • Frankel Stanley
    Director
    Bought
    Date
    28 September 2026
    Shares
    1,000
    Price
    $6.00
    Value
    $6,000
  • Brown Melinda
    Director
    Bought
    Date
    25 September 2026
    Shares
    1,135
    Price
    $6.27
    Value
    $7,116
  • Germano Geno J
    Director
    Bought
    Date
    25 September 2026
    Shares
    2,609
    Price
    $6.28
    Value
    $16,385
  • Amoroso Michael
    President and CEO, Director
    Sold
    under a preset trading plan
    Date
    18 February 2026
    Shares
    20,559
    Price
    $3.84
    Value
    $78,947
  • Kelly John Alexander
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    18 February 2026
    Shares
    8,149
    Price
    $3.84
    Value
    $31,292
  • Scimeca Dario
    General Counsel and Secretary
    Sold
    under a preset trading plan
    Date
    18 February 2026
    Shares
    4,925
    Price
    $3.84
    Value
    $18,912
  • SMITH J. JEFFERSON
    Chief Research Officer
    Sold
    under a preset trading plan
    Date
    18 February 2026
    Shares
    4,925
    Price
    $3.84
    Value
    $18,912
  • Amoroso Michael
    President and CEO, Director
    Sold
    under a preset trading plan
    Date
    22 January 2026
    Shares
    34,799
    Price
    $4.17
    Value
    $145,112
  • Scimeca Dario
    General Counsel and Secretary
    Sold
    under a preset trading plan
    Date
    21 January 2026
    Shares
    8,854
    Price
    $4.03
    Value
    $35,682
  • Kelly John Alexander
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    21 January 2026
    Shares
    15,213
    Price
    $4.03
    Value
    $61,308

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 12 Mar 2026, plus the 10-Q filed 6 Aug 2026 and 9 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.